Biogen Ceases Aduhelm Program, Shifts Focus to Leqembi
TL;DR Summary
Biogen is relinquishing its ownership of Aduhelm, the controversial Alzheimer's disease treatment, allowing Neurimmune to regain full rights to the drug. The decision also involves terminating an ongoing clinical trial aimed at demonstrating the treatment's benefits for early-stage Alzheimer's patients. Biogen's CEO emphasized Aduhelm's role in paving the way for new drug development in the field.
- Years after a polarizing approval, Biogen walks away from Aduhelm STAT
- Biogen Ends Aduhelm Program in Shift of Alzheimer's Resources The Wall Street Journal
- Biogen drops controversial Alzheimer's drug MarketWatch
- Biogen discontinues first Alzheimer's drug, goes all-in on Leqembi - Boston Business Journal The Business Journals
- Biogen Will Stop Selling, Testing Alzheimer's Drug Aduhelm Bloomberg
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
57%
129 → 56 words
Want the full story? Read the original article
Read on STAT